BioSpace News Archive

William Jarosz, the Chief Executive Officer of iCo commented, “We deeply appreciate this show of support from our warrant holders.

Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 5,135,135 common shares, which includes 810,810 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase 1,081,081 common shares.

CAE Inc. (“CAE” or the “Corporation”) today announced the closing of its previously announced underwritten marketed public offering of common shares in the United States and Canada (the “Offering”). CAE issued a total of 10,454,545 shares, including 1,363,636 shares following the exercise in full by the underwriters of their over-allotment option

Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company, announced today an agreement with Amzell B.V. (Amzell) that will further strengthen its position in the marketplace with the commercial rights to one of Amzell’s leading clinical-stage programs that will bring a critical and accessible therapy for patients in need.

Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s fourth quarter 2020 financial results will be released on Tuesday, March 16, 2021.

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Company’s management will be participating in the KeyBanc Life Sciences & MedTech Investor Forum.

National Health Investors, Inc. (NYSE:NHI) announced today that it will pay its first quarter dividend of $1.1025 per common share on May 7, 2021 to shareholders of record as of March 31, 2021.

Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will host a conference call to discuss its 2020 financial results and provide a business update at 8:30 a.m. ET on Thursday, March 18, 2021.

Quantum Leap Healthcare Collaborative (QLHC), the sponsor of the I-SPY COVID Trial, announced that apremilast (Otezla), made by Amgen, has been dropped for futility

Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that long-term follow up data from MINDACT, the prospective, randomized trial designed to further confirm the clinical utility of MammaPrint® risk scoring when determining a breast cancer patient’s need for chemotherapy, was published in The Lancet Oncology, and can be viewed online here.